Labiotech.eu

News and Trends 6 Sep 2022

IRLAB’s partner Ipsen starts mesdopetam clinical studies

IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […]

September 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

Synaffix and Emergence in $360M technology platform deal to develop ADCs

Dutch biotech Synaffix B.V. and German Emergence Therapeutics announced today (September 6) they have entered into a licensing agreement of up to $360 million. The agreement will provide Emergence access on a target-specific basis to Synaffix’s antibody drug conjugate (ADC) technologies made up of Glycoconnect, HydraSpace and SYNtecan E linker payload. Under the terms of […]

September 6, 2022 - 2 minutesmins - By Liza Laws

Forsea Foods is relieving bottleneck in seafood supply starting with eel meat

News and Trends 6 Sep 2022

Forsea Foods creates eel meat using patented organoid technology

Cell cultured seafood produced with the same nutrients and texture has been developed through patented organoid technology. Previously used in developmental biology, medicine and research, organoids are stem cell-derived, three-dimensional tissue structures that, when used in cell-cultured seafood products, require only a minimal amount of growth factors. Forsea Foods Ltd. has announced it is beginning […]

September 6, 2022 - 3 minutesmins - By Liza Laws

News and Trends 6 Sep 2022

Salipro Biotech obtains patents for direct extraction of membrane proteins and library generation

Salipro Biotech AB, a Swedish biotech company with a platform for the stabilization of membrane proteins for drug development, has had patents issued by both the U.S. Patent and Trademark Office and the China National Intellectual Property Administration. The patent is entitled “Saposin lipoprotein particles and libraries from crude membranes.” The patents cover the company’s […]

September 6, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

Innovent starts trial of mazdutide in Chinese adults with obesity

Innovent Biologics, Inc. says the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical trial of mazdutide, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity. This randomized, double-blinded, placebo-controlled study was designed to evaluate the efficacy and safety of mazdutide […]

September 6, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

Pleco Therapeutics raises €17.3M to develop AML product

Pleco Therapeutics BV, a specialty biopharmaceutical company in the Netherlands developing novel treatments designed to detoxify the cancer micro-environment has raised total funds of €17.3 million ($17.2 million) in series A financing. The funds will be used to complete development of, and to commercialize, the company’s novel lead Plecoid product, PTX-061, to improve the effectiveness […]

September 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

The first patient has been dosed in a phase 2 trial looking at a drug to treat peripheral T cell lymphomas – a heterogenous group of generally aggressive neoplasms. Yingli Pharma made the announcement on Saturday (September 3) that patients were being dosed with linperlisib – a potent inhibitor of the delta isoform of PI3 […]

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […]

September 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Sanofi and Regeneron’s Dupixent shows sustained improvement in lung function in children

A maintenance therapy from Sanofi and Regeneron, added to other asthma medications, has shown sustained improvement in lung function, low-rate of asthma attacks and a consistent safety profile for up to two years in children. Results from the longest global phase 3 open-label extension trial in the age group six to 11 years old with […]

September 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

Astellas ‘encouraged’ by menopause symptom treatment results in China

Astellas Pharma Inc. has announced topline results from its phase 3 MOONLIGHT 3 clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night […]

September 5, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral infection and recovery in hospital patients. The UNIVERSAL (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal) trial is an observational study being led by the Clinical Trials Unit of the University of Southampton in the U.K. to explore and […]

September 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

A drug to treat soft tissue sarcoma has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Clinical stage oncology drug company Avacta Group plc has produced a form of the generic chemotherapy, doxorubicin AVA6000. About Avacta’s drug The drug has been modified using the company’s pre|CISION technology and Affirmer […]

September 5, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

IRLAB’s partner Ipsen starts mesdopetam clinical studies

Synaffix and Emergence in $360M technology platform deal to develop ADCs

Forsea Foods creates eel meat using patented organoid technology

Salipro Biotech obtains patents for direct extraction of membrane proteins and library generation

Innovent starts trial of mazdutide in Chinese adults with obesity

Pleco Therapeutics raises €17.3M to develop AML product

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

Sanofi and Regeneron’s Dupixent shows sustained improvement in lung function in children

Astellas ‘encouraged’ by menopause symptom treatment results in China

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!